The fact that AAT has been proven to be a safe drug that has been used effectively for the treatment of pulmonary emphysema in patients with hereditary deficiency of AAT for decades [16] would facilitate the use of AAT for the treatment of T2D. This evidence concerns the gene SERPINA1 and pulmonary emphysema.